已收盤 09-26 16:00:00 美东时间
+0.310
+8.31%
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
The latest update is out from Clearside Biomedical ( ($CLSD) ). On September 10...
09-11 19:48
Clearside Biomedical ( ($CLSD) ) just unveiled an announcement. On September 4,...
09-08 19:52
Clearside Biomedical ( ($CLSD) ) has shared an update. On August 28, 2025, Clea...
09-04 05:02
- Presentations Highlight the Versatility of Clearside's SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -- CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in
08-26 20:11
Clearside Biomedical ( ($CLSD) ) has shared an announcement. On February 7, 202...
08-15 04:28
Clearside Biomedical's XIPERE, an injectable corticosteroid for treating uveitic macular edema, has received approval in the U.S., Canada, Australia, and Singapore, with regulatory reviews ongoing in China. The drug is administered via the company's proprietary suprachoroidal space (SCS) injection platform, utilizing the SCS Microinjector, which allows precise drug delivery to the back of the eye. Clearside is expanding its global presence and ad...
07-23 11:05
Gainers Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 90.1% to $2.3 during...
07-19 01:06
今日重点评级关注:花旗:维持百度"买入"评级,目标价从138美元升至140美元;Maxim Group:维持Caledonia Mining"买入"评级,目标价从21美元升至28美元
07-18 09:25
Clearside Biomedical, Inc. announced plans to explore strategic alternatives to maximize shareholder value, including asset sales, licensing, or collaborations. The company's SCS Microinjector platform enables non-surgical delivery of therapies to the back of the eye, with approved products in the U.S., Singapore, and Australia. Its CLS-AX program for wet AMD achieved positive Phase 2b results and FDA alignment for a Phase 3 trial. Clearside has ...
07-17 11:05